Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... Roche's MS drug is among major drugs still to come in 2016.
News European safety experts review latest hepatitis C drugs European safety experts are reviewing the latest generation of hepatitis C drugs following cases of re-activation of hepatitis B in patients treated with the medicines, who had been infecte
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
